These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 32497550)

  • 81. Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications.
    Ardini E; Menichincheri M; Banfi P; Bosotti R; De Ponti C; Pulci R; Ballinari D; Ciomei M; Texido G; Degrassi A; Avanzi N; Amboldi N; Saccardo MB; Casero D; Orsini P; Bandiera T; Mologni L; Anderson D; Wei G; Harris J; Vernier JM; Li G; Felder E; Donati D; Isacchi A; Pesenti E; Magnaghi P; Galvani A
    Mol Cancer Ther; 2016 Apr; 15(4):628-39. PubMed ID: 26939704
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Apatinib Reverses Paclitaxel-resistant Lung Cancer Cells (A549) Through Blocking the Function of ABCB1 Transporter.
    Zhang Q; Song Y; Cheng X; Xu Z; Matthew OA; Wang J; Sun Z; Zhang X
    Anticancer Res; 2019 Oct; 39(10):5461-5471. PubMed ID: 31570440
    [TBL] [Abstract][Full Text] [Related]  

  • 83. OATP1A/1B, CYP3A, ABCB1, and ABCG2 limit oral availability of the NTRK inhibitor larotrectinib, while ABCB1 and ABCG2 also restrict its brain accumulation.
    Wang Y; Sparidans RW; Li W; Lebre MC; Beijnen JH; Schinkel AH
    Br J Pharmacol; 2020 Jul; 177(13):3060-3074. PubMed ID: 32087611
    [TBL] [Abstract][Full Text] [Related]  

  • 84. FRAX486, a PAK inhibitor, overcomes ABCB1-mediated multidrug resistance in breast cancer cells.
    Zhang M; Zeng X; She M; Dong X; Chen J; Xiong Q; Qiu G; Yang S; Li X; Ren G
    Braz J Med Biol Res; 2024; 57():e13357. PubMed ID: 38958364
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Isobavachalcone as an Active Membrane Perturbing Agent and Inhibitor of ABCB1 Multidrug Transporter.
    Palko-Łabuz A; Błaszczyk M; Środa-Pomianek K; Wesołowska O
    Molecules; 2021 Jul; 26(15):. PubMed ID: 34361789
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Paynantheine more effectively reverses multidrug resistance in malignant EPG85.257RDB and MCF7MX cells than morphine and speciociliatine.
    Abdali N; Nadipour Borujeni M; Hosseini SA; Malekzadeh R; Abolhasani M; Mirzaei SA; Elahian F
    Cell Biol Int; 2024 Jun; 48(6):861-871. PubMed ID: 38480672
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Entrectinib, a TRK/ROS1 inhibitor with anti-CNS tumor activity: differentiation from other inhibitors in its class due to weak interaction with P-glycoprotein.
    Fischer H; Ullah M; de la Cruz CC; Hunsaker T; Senn C; Wirz T; Wagner B; Draganov D; Vazvaei F; Donzelli M; Paehler A; Merchant M; Yu L
    Neuro Oncol; 2020 Jun; 22(6):819-829. PubMed ID: 32383735
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Entrectinib for the treatment of metastatic NSCLC: safety and efficacy.
    Sartore-Bianchi A; Pizzutilo EG; Marrapese G; Tosi F; Cerea G; Siena S
    Expert Rev Anticancer Ther; 2020 May; 20(5):333-341. PubMed ID: 32223357
    [No Abstract]   [Full Text] [Related]  

  • 89. HM30181 Derivatives as Novel Potent and Selective Inhibitors of the Breast Cancer Resistance Protein (BCRP/ABCG2).
    Köhler SC; Wiese M
    J Med Chem; 2015 May; 58(9):3910-21. PubMed ID: 25855895
    [TBL] [Abstract][Full Text] [Related]  

  • 90. P-Glycoprotein (ABCB1/MDR1) Controls Brain Penetration and Intestinal Disposition of the PARP1/2 Inhibitor Niraparib.
    F Martins ML; Loos NHC; Mucuk S; de Jong D; Lebre MC; Rosing H; Tibben M; Beijnen JH; Schinkel AH
    Mol Pharm; 2021 Dec; 18(12):4371-4384. PubMed ID: 34730366
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Discovery of phenylselenoether-hydantoin hybrids as ABCB1 efflux pump modulating agents with cytotoxic and antiproliferative actions in resistant T-lymphoma.
    Ali W; Spengler G; Kincses A; Nové M; Battistelli C; Latacz G; Starek M; Dąbrowska M; Honkisz-Orzechowska E; Romanelli A; Rasile MM; Szymańska E; Jacob C; Zwergel C; Handzlik J
    Eur J Med Chem; 2020 Aug; 200():112435. PubMed ID: 32505850
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Interactions between Maraviroc and the ABCB1, ABCG2, and ABCC2 Transporters: An Important Role in Transplacental Pharmacokinetics.
    Tupova L; Ceckova M; Ambrus C; Sorf A; Ptackova Z; Gaborik Z; Staud F
    Drug Metab Dispos; 2019 Sep; 47(9):954-960. PubMed ID: 31266750
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Grid-independent Descriptors (GRIND) Analysis and SAR Guided Molecular Docking Studies to Probe Selectivity Profiles of Inhibitors of Multidrug Resistance Transporters ABCB1 and ABCG2.
    Shafi T; Jabeen I
    Curr Cancer Drug Targets; 2017; 17(2):177-190. PubMed ID: 27585695
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Novel Potent ABCB1 Modulator, Phenethylisoquinoline Alkaloid, Reverses Multidrug Resistance in Cancer Cell.
    Sugisawa N; Ohnuma S; Ueda H; Murakami M; Sugiyama K; Ohsawa K; Kano K; Tokuyama H; Doi T; Aoki J; Ishida M; Kudoh K; Naitoh T; Ambudkar SV; Unno M
    Mol Pharm; 2018 Sep; 15(9):4021-4030. PubMed ID: 30052463
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Identification of Thienopyrimidine Scaffold as an Inhibitor of the ABC Transport Protein ABCC1 (MRP1) and Related Transporters Using a Combined Virtual Screening Approach.
    Silbermann K; Stefan SM; Elshawadfy R; Namasivayam V; Wiese M
    J Med Chem; 2019 May; 62(9):4383-4400. PubMed ID: 30925062
    [TBL] [Abstract][Full Text] [Related]  

  • 96. ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis.
    Cotte S; von Ahsen N; Kruse N; Huber B; Winkelmann A; Zettl UK; Starck M; König N; Tellez N; Dörr J; Paul F; Zipp F; Lühder F; Koepsell H; Pannek H; Montalban X; Gold R; Chan A
    Brain; 2009 Sep; 132(Pt 9):2517-30. PubMed ID: 19605531
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Bufalin reverses ABCB1-mediated drug resistance in colorectal cancer.
    Yuan ZT; Shi XJ; Yuan YX; Qiu YY; Zou Y; Liu C; Yu H; He X; Xu K; Yin PH
    Oncotarget; 2017 Jul; 8(29):48012-48026. PubMed ID: 28624793
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Physiologically-Based Pharmacokinetic Modelling of Entrectinib Parent and Active Metabolite to Support Regulatory Decision-Making.
    Djebli N; Buchheit V; Parrott N; Guerini E; Cleary Y; Fowler S; Frey N; Yu L; Mercier F; Phipps A; Meneses-Lorente G
    Eur J Drug Metab Pharmacokinet; 2021 Nov; 46(6):779-791. PubMed ID: 34495458
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Heterocyclic cyclohexanone monocarbonyl analogs of curcumin can inhibit the activity of ATP-binding cassette transporters in cancer multidrug resistance.
    Revalde JL; Li Y; Hawkins BC; Rosengren RJ; Paxton JW
    Biochem Pharmacol; 2015 Feb; 93(3):305-17. PubMed ID: 25543853
    [TBL] [Abstract][Full Text] [Related]  

  • 100. ABCB1 restricts brain accumulation of the novel RORγ agonist cintirorgon, while OATP1A/1B and CYP3A limit its oral availability.
    Li W; Lehutová D; Sparidans RW; Heydari P; Wang J; Lebre MC; Beijnen JH; Schinkel AH
    Eur J Pharm Biopharm; 2022 Aug; 177():135-146. PubMed ID: 35772614
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.